Clinical Trials Logo

Clinical Trial Summary

Parkinson's disease (PD) is one of the most common neurodegenerative diseases, with a higher prevalence in the elderly. Levodopa induced dyskinesias (LID) are a major motor complications that impair quality of life for patients with PD. The mechanisms of these dyskinesias remain unclear, but several hypotheses have been put forward: non continuous, pulsatile stimulation of dopaminergic receptors, or alterations of other neurotransmitters within the motor striatum such as glutamate and serotonin. Few strategies are now available to treat severe LID: - Medications: reduction of dopaminergic treatment, addition of amantadine, - Functional neurosurgery. The purpose of this study is to investigate the efficacy of buspirone in PD patients suffering from dyskinesias. The role of serotonin in the occurrence of LID was recently demonstrated in transplant PD patients and a test double-blind, single dose was achieved. Following administration of 10 mg oral buspirone, a 5HT1A agonist, LID were clearly improved. A antidyskinetic effect of buspirone had already been reported in 1991 and 1994, but identification of buspirone as a serotonin receptor agonist has been reported more recently. This trial is aimed at (1) validate the serotoninergic hypothesis of hyperkinetic levodopa induced dyskinesias (LID) in Pakinson's disease patients, (2) evaluate, in a phase 3 trial, the motor efficacy of buspirone to improve LID vs placebo, (3) look at a possible dose/effect relationship and (4) check the hypothesis of a better therapeutic ratio using the association of buspirone and amantadine instead than a single drug.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02617017
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact
Status Completed
Phase Phase 3
Start date June 17, 2016
Completion date March 23, 2023

See also
  Status Clinical Trial Phase
Completed NCT06037590 - A Pilot Comparative Bioavailability Study of Levodopa Administered Via Levodopa Cyclops™ Relative to INBRIJA® Phase 1
Recruiting NCT01537224 - Electrophysiological Activity of the Subthalamic Nucleus During the Processing of Emotional and Motivational Information N/A
Withdrawn NCT04011449 - State-dependent Pathophysiological Oscillations in Parkinson's Disease and Treatment With DBS Using the Medtronic RC+S N/A
Completed NCT02539446 - Suprapostural Attention Focus and Postural Difficulty on H-reflex and Brain Activity: Aging and Parkinson's Disease N/A
Completed NCT00358189 - Effects of Deep Brain Stimulation for the Treatment of Parkinson's Disease N/A
Active, not recruiting NCT04606979 - tDCS of the Primary Motor Cortex to Improve Implicit Motor Sequence Learning in Parkinson's Disease N/A
Completed NCT05119803 - The Relationship of Spine Posture and Mobility With Upper Extremity Functions in Parkinson's Patients
Recruiting NCT06154772 - Quality of Life, Anxiety and Fatigue Level of Parkison's Patients With Color Therapy N/A
Not yet recruiting NCT02249715 - Development of a Monitoring Set-up and Algorithm Using Functional MRI (fMRI) and EEG for Prediction of Response to Repetitive Deep Transcranial Magnetic Stimulation (rDTMS) for Patients With Parkinson's Disease N/A
Completed NCT01732653 - A Treadmill Training Program Augmented by Virtual Reality to Decrease Fall Risk in Older Adults N/A
Completed NCT03232996 - Evaluation of a Computer Game Based Rehabilitation System for Assessment and Treatment of Balance and Gait Impairments in Individuals With Parkinson's Disease. N/A
Enrolling by invitation NCT04566341 - Study of Gastrointestinal Dysfunction and Enteric Neural Pathology in Patients With Parkinson's Disease
Active, not recruiting NCT04978597 - Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study) Phase 3
Recruiting NCT06116084 - Randomized Controlled Study Evaluating the Efficacy of Hypnosis in Nuclear Medicine N/A
Recruiting NCT05830396 - GRoningen Early-PD Ambroxol Treatment Phase 2/Phase 3
Not yet recruiting NCT05379062 - Choral Singing for Patients With Parkinson's N/A
Completed NCT02071823 - Comparative Bioavailability Study of BIA 9-1067 25 mg Capsules Phase 1
Recruiting NCT03558568 - The Effect of Deep Brain Stimulation on Facial Expressions. N/A
Enrolling by invitation NCT05596201 - Super-resolution of Brain Magnetic Resonance Images in Deep Brain Stimulation for Parkinson's Disease
Recruiting NCT04181918 - Action Observation Treatment in Parkinson's Patients N/A